{
    "nct_id": "NCT05873439",
    "official_title": "A Feasibility Study of Genomically Guided Radiation Dose Personalization in the Management of Locally Advanced Non-Small Cell Lung Cancer",
    "inclusion_criteria": "* Diagnosis of AJCC Stage 2 or Stage 3 unresectable NSCLC as determined by a multidisciplinary oncology team\n* Confirmation of NSCLC with availability of fresh tumor biopsy by tissue biopsy which can include adenocarcinoma, squamous cell, large cell carcinoma, or NSCLC not otherwise specified\n* Life expectancy >12 weeks\n* Normal renal (creatinine <1.5 × upper limit of normal [ULN]), liver (bilirubin < 1.5 × ULN, transaminases <3.0 × ULN, except in known hepatic disease, wherein may be <5 × ULN) and blood counts (white blood cells ≥2.5, neutrophils ≥1000, platelets ≥50, 000, hemoglobin ≥8)\n* ECOG 0-1\n* Age ≥ 18 years\n* Participants with surgery within 14 days should have recovered from all effects of the surgery and be cleared by their surgeon\n* There is no limit on prior systemic or therapies\n* Women of childbearing potential and sexually active males must commit to the use of effective contraception while on study\n* Ability to sign an informed consent form, which can be signed by a family member or health care proxy. Informed consent must be given before any study related procedures occur.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Current or prior participation in a study of an investigational agent or investigational device within 2 weeks of the first dose of study treatment\n* Major surgery or significant traumatic injury that has not been recovered from 14 days before the initiation of study drug\n* Women who are pregnant or breastfeeding\n* History of allergy or hypersensitivity to any of the study drugs or study drug components\n* Concurrent brain metastases or leptomeningeal disease\n* History of prior malignancy within 2 years prior to screening, with the exception of those with a negligible risk of metastasis or death (e.g., 5-year OS of > 90%), such as but not limited to, non-melanoma skin carcinoma, ductal carcinoma in situ, or stage I endometriod uterine cancer, and others at the discretion of the PI\n* Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [eg, colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc]). The following are exceptions to this criterion:\n* • Patients with vitiligo or alopecia\n* • Patients with hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement\n* • Any chronic skin condition that does not require systemic therapy\n* • Patients without active disease in the last 5 years may be included but only after consultation with the Principal Investigator\n* • Patients with celiac disease controlled by diet alone\n* Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab. The following are exceptions to this criterion:\n* • Intranasal, inhaled, topical steroids, or local steroid injections (eg, intra articular injection)\n* • Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent\n* • Steroids as premedication for hypersensitivity reactions (eg, CT scan premedication)",
    "miscellaneous_criteria": ""
}